Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

(2017) Marie D. Ralff et al.   MOLECULAR CANCER THERAPEUTICS

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).

(2017) C. J. Langer et al.   JOURNAL OF CLINICAL ONCOLOGY

C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer

(2014) Fenglin Zang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

(2014) Martina SJ McDermott et al.   Molecular Cancer

Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis

(2013) Á. C. Murphy et al.   APOPTOSIS

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer

(2012) G. Gullo et al.   ANNALS OF ONCOLOGY

Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells

(2012) S. Mazumder et al.   CANCER RESEARCH

Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms

(2012) Jamal Joudeh et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

(2012) L Y Dimberg et al.   ONCOGENE

Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis

(2011) Melisa A. Martínez-Paniagua et al.   CELL CYCLE

Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma

(2011) D. Opel et al.   CLINICAL CANCER RESEARCH

The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells

(2011) K. Zitzmann et al.   ENDOCRINE-RELATED CANCER

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

(2011) B N Rexer et al.   ONCOGENE

Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation

(2011) N. G. Dolloff et al.   Science Translational Medicine

Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy

(2010) Aditi Pandya Martin et al.   CANCER BIOLOGY & THERAPY

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

(2010) Clint Mitchell et al.   CANCER BIOLOGY & THERAPY

Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer

(2010) Eitan Amir et al.   CANCER TREATMENT REVIEWS

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells

(2010) Norma O’Donovan et al.   INVESTIGATIONAL NEW DRUGS

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

(2010) N. A. O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells

(2009) Soo-Jung Park et al.   CELLULAR SIGNALLING

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells

(2008) P. L. Tazzari et al.   CANCER RESEARCH

BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

(2008) S. Huang et al.   CLINICAL CANCER RESEARCH

Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells

(2008) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

(2008) A. P. Martin et al.   MOLECULAR PHARMACOLOGY

FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells

(2008) A N Cornforth et al.   ONCOGENE